Comparison of the Anti-tumor Effects of Selective Serotonin Reuptake Inhibitors as Well as Serotonin and Norepinephrine Reuptake Inhibitors in Human Hepatocellular Carcinoma Cells

Biological & Pharmaceutical Bulletin
Jun KuwaharaSatohiro Masuda

Abstract

The anti-tumor effects of selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) on several types of cancer cells have been reported. However, comparison of the anti-tumor effects of these drugs on human hepatocellular carcinoma (HepG2) cells has not been studied. We compared the anti-tumor effects of four SSRIs and two SNRIs on HepG2 cells. SSRIs and duloxetine dose-dependently decreased cell viability. Milnacipran had no effect on cell viability. The half-maximal inhibitory concentration was lower in the order of: sertraline, paroxetine, duloxetine, fluvoxamine, escitalopram, and milnacipran. Exposure to sertraline (2 µM) significantly increased caspase-3/7 activity. These results suggest that, of the agents tested here, sertraline had the highest sensitivity to HepG2 cells, and activation of the caspase pathway is involved in the anti-tumor effects of sertraline in HepG2 cells.

References

Mar 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·S RamamoorthyR D Blakely
Dec 31, 1996·Brain Research. Molecular Brain Research·A S ChangR D Blakely
Aug 16, 2003·Drug Metabolism and Disposition : the Biological Fate of Chemicals·R J LantzM P Knadler
Jan 24, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Valérie BoigeMichel Ducreux
Jun 16, 2007·Gastroenterology·Hashem B El-Serag, K Lenhard Rudolph
Jul 25, 2008·The New England Journal of Medicine·Josep M LlovetUNKNOWN SHARP Investigators Study Group
Jul 28, 2009·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Ben Hayman AmitAbraham Weizman
Mar 5, 2011·Basic & Clinical Pharmacology & Toxicology·Jong-Khing HuangChung-Ren Jan
Jun 2, 2012·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Fanying LiJohn Ho
Oct 23, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Christopher SollPierre-Alain Clavien
Nov 14, 2012·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Angela Gauthier, Mitchell Ho
Dec 21, 2012·Journal of Neural Transmission·S UntereckerB Pfuhlmann
Oct 1, 2013·Breast Cancer Research and Treatment·Lærke Toftegård AndersenIsmail Gögenur
Nov 7, 2013·Toxicological Sciences : an Official Journal of the Society of Toxicology·Si ChenLei Guo
Nov 12, 2013·Journal of the Egyptian National Cancer Institute·Omar Abdel-Rahman
Feb 28, 2014·World Journal of Hepatology·Joo-Hyun KimDae-Yeul Yu

❮ Previous
Next ❯

Citations

Nov 12, 2016·Trends in Neurosciences·Jami L SalomanBrian M Davis
Aug 2, 2018·BMC Research Notes·Ed Carlos Rey MouraRioko Kimiko Sakata
Nov 14, 2018·Journal of Cellular and Molecular Medicine·Won-Jun JangChul-Ho Jeong
Jul 15, 2017·Current Opinion in Clinical Nutrition and Metabolic Care·Klaske van NorrenRenger F Witkamp
Jun 25, 2016·International Journal of Molecular Sciences·Benoît RanchouxSébastien Bonnet
Jul 1, 2020·Cancers·Sabina SanegreTomás Álvaro Naranjo
Jun 20, 2017·Oncology Reports·Dong Kwon Yang, Shang-Jin Kim
Sep 15, 2020·Frontiers in Oncology·Mariana Avendaño-FélixRosalío Ramos-Payán

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.